Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody-Reference-Cited by-同舟云学术

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

Published:2008-08-15 Issue:5891 Volume:321 Page:974-977
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Bargou Ralf¹²³⁴⁵,Leo Eugen¹²³⁴⁵,Zugmaier Gerhard¹²³⁴⁵,Klinger Matthias¹²³⁴⁵,Goebeler Mariele¹²³⁴⁵,Knop Stefan¹²³⁴⁵,Noppeney Richard¹²³⁴⁵,Viardot Andreas¹²³⁴⁵,Hess Georg¹²³⁴⁵,Schuler Martin¹²³⁴⁵,Einsele Hermann¹²³⁴⁵,Brandl Christian¹²³⁴⁵,Wolf Andreas¹²³⁴⁵,Kirchinger Petra¹²³⁴⁵,Klappers Petra¹²³⁴⁵,Schmidt Margit¹²³⁴⁵,Riethmüller Gert¹²³⁴⁵,Reinhardt Carsten¹²³⁴⁵,Baeuerle Patrick A.¹²³⁴⁵,Kufer Peter¹²³⁴⁵

Affiliation:

1. Interdisciplinary Phase I/II Unit of the University of Würzburg, Klinikstraße 6-8, 97070 Würzburg, Germany.

2. Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Klinikstraße 6-8, 97070 Würzburg, Germany.

3. Micromet AG, Staffelseestraße 2, 81477 Munich, Germany; and Micromet, Incorporated, 6707 Democracy Boulevard, Bethesda, MD 20817, USA.

4. Universitätsklinikum Essen, Klinik für Hämatologie, Medizinische Klinik und Poliklinik, Hufelandstraße 55, 45147 Essen, Germany.

5. Universitätsklinikum Ulm, Innere Medizin III, Robert-Koch-Straße 8, 89081 Ulm, Germany.

Abstract

Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non–Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell–engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference30 articles.

1. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

2. Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

3. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

4. S. Gross, P. Walden, Immunol. Lett.116, 7 (2008).

5. L. F. Langer, M. F. Clay, M. A. Morse, Expert Opin. Biol. Ther.7, 1245 (2007).

Cited by 905 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blinatumomab consolidation post–autologous stem cell transplantation in patients with diffuse large B-cell lymphoma;Blood Advances;2024-02-13

2. Engineered platelet-based immune engager for tumor post-surgery treatment;Biomaterials Advances;2024-02

3. In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies;2024-01-31

4. Subcutaneous Administration of Monoclonal Antibodies: Pharmacology, Delivery, Immunogenicity, and Learnings From Applications to Clinical Development;Clinical Pharmacology & Therapeutics;2024-01-10

5. Recent applications of RNA therapeutic in clinics;Progress in Molecular Biology and Translational Science;2024